Literature DB >> 17299050

Resistance of human T cell leukemia virus type 1 to APOBEC3G restriction is mediated by elements in nucleocapsid.

David Derse1, Shawn A Hill, Gerald Princler, Patricia Lloyd, Gisela Heidecker.   

Abstract

Human T cell leukemia virus type 1 (HTLV-1) has evolved a remarkable strategy to thwart the antiviral effects of the cellular cytidine deaminase APOBEC3G (hA3G). HTLV-1 infects T lymphocytes in vivo, where, like HIV-1, it is likely to encounter hA3G. HIV-1 counteracts the innate antiviral activity of hA3G by producing an accessory protein, Vif, which hastens the degradation of hA3G. In contrast, HTLV-1 does not encode a Vif homologue; instead, HTLV-1 has evolved a cis-acting mechanism to prevent hA3G restriction. We demonstrate here that a peptide motif in the C terminus of the HTLV-1 nucleocapsid (NC) domain inhibits hA3G packaging into nascent virions. Mutation of amino acids within this region resulted in increased levels of hA3G incorporation into virions and increased susceptibility to hA3G restriction. Elements within the C-terminal extension of the NC domain are highly conserved among the primate T cell leukemia viruses, but this extension is absent in all other retroviral NC proteins.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17299050      PMCID: PMC1815281          DOI: 10.1073/pnas.0609444104

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  36 in total

1.  DNA deamination mediates innate immunity to retroviral infection.

Authors:  Reuben S Harris; Kate N Bishop; Ann M Sheehy; Heather M Craig; Svend K Petersen-Mahrt; Ian N Watt; Michael S Neuberger; Michael H Malim
Journal:  Cell       Date:  2003-06-13       Impact factor: 41.582

2.  Antiviral function of APOBEC3G can be dissociated from cytidine deaminase activity.

Authors:  Edmund N C Newman; Rebecca K Holmes; Heather M Craig; Kevin C Klein; Jaisri R Lingappa; Michael H Malim; Ann M Sheehy
Journal:  Curr Biol       Date:  2005-01-26       Impact factor: 10.834

3.  Complementary function of the two catalytic domains of APOBEC3G.

Authors:  Francisco Navarro; Brooke Bollman; Hui Chen; Renate König; Qin Yu; Kristopher Chiles; Nathaniel R Landau
Journal:  Virology       Date:  2005-03-15       Impact factor: 3.616

4.  Cellular APOBEC3G restricts HIV-1 infection in resting CD4+ T cells.

Authors:  Ya-Lin Chiu; Vanessa B Soros; Jason F Kreisberg; Kim Stopak; Wes Yonemoto; Warner C Greene
Journal:  Nature       Date:  2005-04-13       Impact factor: 49.962

5.  The enzymatic activity of CEM15/Apobec-3G is essential for the regulation of the infectivity of HIV-1 virion but not a sole determinant of its antiviral activity.

Authors:  Keisuke Shindo; Akifumi Takaori-Kondo; Masayuki Kobayashi; Aierken Abudu; Keiko Fukunaga; Takashi Uchiyama
Journal:  J Biol Chem       Date:  2003-09-11       Impact factor: 5.157

6.  Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif.

Authors:  Roberto Mariani; Darlene Chen; Bärbel Schröfelbauer; Francisco Navarro; Renate König; Brooke Bollman; Carsten Münk; Henrietta Nymark-McMahon; Nathaniel R Landau
Journal:  Cell       Date:  2003-07-11       Impact factor: 41.582

7.  Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts.

Authors:  Bastien Mangeat; Priscilla Turelli; Gersende Caron; Marc Friedli; Luc Perrin; Didier Trono
Journal:  Nature       Date:  2003-05-28       Impact factor: 49.962

8.  HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation.

Authors:  Mariana Marin; Kristine M Rose; Susan L Kozak; David Kabat
Journal:  Nat Med       Date:  2003-10-05       Impact factor: 53.440

9.  HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability.

Authors:  Kim Stopak; Carlos de Noronha; Wes Yonemoto; Warner C Greene
Journal:  Mol Cell       Date:  2003-09       Impact factor: 17.970

10.  The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif.

Authors:  Ann M Sheehy; Nathan C Gaddis; Michael H Malim
Journal:  Nat Med       Date:  2003-10-05       Impact factor: 53.440

View more
  79 in total

Review 1.  Single-molecule stretching studies of RNA chaperones.

Authors:  Hao Wu; Ioulia Rouzina; Mark C Williams
Journal:  RNA Biol       Date:  2010-11-01       Impact factor: 4.652

2.  Leveraging APOBEC3 proteins to alter the HIV mutation rate and combat AIDS.

Authors:  Judd F Hultquist; Reuben S Harris
Journal:  Future Virol       Date:  2009-11-01       Impact factor: 1.831

3.  Gag localization and virus-like particle release mediated by the matrix domain of human T-lymphotropic virus type 1 Gag are less dependent on phosphatidylinositol-(4,5)-bisphosphate than those mediated by the matrix domain of HIV-1 Gag.

Authors:  Jingga Inlora; Vineela Chukkapalli; David Derse; Akira Ono
Journal:  J Virol       Date:  2011-02-02       Impact factor: 5.103

Review 4.  Nucleocapsid protein function in early infection processes.

Authors:  James A Thomas; Robert J Gorelick
Journal:  Virus Res       Date:  2008-02-14       Impact factor: 3.303

5.  Species-specific inhibition of APOBEC3C by the prototype foamy virus protein bet.

Authors:  Mario Perkovic; Stanislaw Schmidt; Daniela Marino; Rebecca A Russell; Benjamin Stauch; Henning Hofmann; Ferdinand Kopietz; Björn-Philipp Kloke; Jörg Zielonka; Heike Ströver; Johannes Hermle; Dirk Lindemann; Vinay K Pathak; Gisbert Schneider; Martin Löchelt; Klaus Cichutek; Carsten Münk
Journal:  J Biol Chem       Date:  2008-12-12       Impact factor: 5.157

6.  Feline Immunodeficiency Virus Vif N-Terminal Residues Selectively Counteract Feline APOBEC3s.

Authors:  Qinyong Gu; Zeli Zhang; Lucía Cano Ortiz; Ana Cláudia Franco; Dieter Häussinger; Carsten Münk
Journal:  J Virol       Date:  2016-11-14       Impact factor: 5.103

7.  TCF1 and LEF1 act as T-cell intrinsic HTLV-1 antagonists by targeting Tax.

Authors:  Guangyong Ma; Jun-ichirou Yasunaga; Hirofumi Akari; Masao Matsuoka
Journal:  Proc Natl Acad Sci U S A       Date:  2015-02-02       Impact factor: 11.205

8.  Single-stranded RNA facilitates nucleocapsid: APOBEC3G complex formation.

Authors:  Hal P Bogerd; Bryan R Cullen
Journal:  RNA       Date:  2008-05-02       Impact factor: 4.942

9.  Equine infectious anemia virus resists the antiretroviral activity of equine APOBEC3 proteins through a packaging-independent mechanism.

Authors:  Hal P Bogerd; Rebecca L Tallmadge; J Lindsay Oaks; Susan Carpenter; Bryan R Cullen
Journal:  J Virol       Date:  2008-09-25       Impact factor: 5.103

10.  David D. Derse, 1949-2009.

Authors:  Maureen Shuh
Journal:  Retrovirology       Date:  2009-12-01       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.